Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials

Mark Nelson(Chelsea and Westminster Hospital), Miklos Salgo(La Roche College), Benoît Trottier, Lucille Donatacci(Vita-Salute San Raffaele University), Christine Katlama(Inserm), Peter J. Piliero(Amsterdam UMC Location University of Amsterdam), Adriano Lazzarin(Vita-Salute San Raffaele University), Bonaventura Clotet(IrsiCaixa), Jacques Reynes(Centre Hospitalier Universitaire de Montpellier), Adeline Valentine(Vita-Salute San Raffaele University), Jain Chung(Vita-Salute San Raffaele University), Daniel R. Kuritzkes(Brigham and Women's Hospital), Mary O’Hearn(Brigham and Women's Hospital), Cynthia Wat(Roche (United Kingdom)), Julio Montaner(University of British Columbia), Denise Guimaraes(Vita-Salute San Raffaele University), Neil Buss, Joseph J. Eron(University of North Carolina at Chapel Hill), Jean-François Delfraissy(Inserm), Keikawus Arastéh(Auguste-Viktoria-Klinik), Ralph DeMasi(Janssen (Belgium)), Lynn Smiley(Brigham and Women's Hospital), Calvin Cohen(Community Research Initiative), Keith Henry(Universität Hamburg), David A. Cooper(UNSW Sydney), Joep M. A. Lange(University of Amsterdam), Sharon Walmsley, Hans-Jürgen Stellbrink(Universität Hamburg), Jacob Lalezari(Quest Clinical Research (United States))

JAIDS Journal of Acquired Immune Deficiency Syndromes

October 26, 2005

Cited by 151

|Hepatology|2006|4.8k

|New England Journal of Medicine|1994|3.7k

|New England Journal of Medicine|2015|1.6k

|JAMA|2008|1k

|JAMA|1998|1k

Related Papers